Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

PHASE4

Phase

COMPLETED

Status

Enrollment

OTHER

Sponsor class

Conditions

DRUG: 0.9% Sodium-chloride
DRUG: Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min
DRUG: Glucagon 12.5ng/kg/min and 0.9% saline
DRUG: 0.9% Sodium-chloride
DRUG: Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min
DRUG: Glucagon 12.5ng/kg/min

Cambridge University Hospitals NHS Foundation Trust